/
Lancet Oncol
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
- D.A. Eichenauer
- A. Plütschow
- S. Kreissl
- M. Sökler
- J.C. Hellmuth
- J. Meissner
- S. Mathas
- M.S. Topp
- K. Behringer
- W. Klapper
- G. Kuhnert
- M. Dietlein
- C. Kobe
- M. Fuchs
- V. Diehl
- A. Engert
- P. Borchmann